{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-018937","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2021-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.173405+00:00","generated_at":"2026-06-29T21:01:16.819253+00:00","sec_items":["2.01","3.01","3.02","8.01","4.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Indaptus Therapeutics completes reverse merger with Decoy Biosystems; begins trading as INDP on Nasdaq","bullets":["Decoy merger closed Aug 3, 2021; exchange ratio of 2.654353395 Indaptus shares per Decoy share.","Post-merger 5,405,963 shares outstanding; Decoy shareholders own 65.6%, Intec Israel owns 34.4%.","Company renamed Indaptus Therapeutics, now a pre-clinical biotech focused on cancer and viral immunotherapy.","Board expanded to eight directors; Michael Newman appointed Chief Scientific Officer; CEO Meckler remains.","Expected to dismiss PWC as auditor and engage Haskell & White for fiscal 2021 audit."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-018937","json":"https://secwatch.observer/filing/0001493152-21-018937.json","markdown":"https://secwatch.observer/filing/0001493152-21-018937.md","text":"https://secwatch.observer/filing/0001493152-21-018937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:01:16.819253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cab8843b6","claim":"Brian O’Callaghan was appointed as Director at Indaptus Therapeutics, Inc..","evidence_excerpt":"each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"71b0fe625e","claim":"Michael Newman was appointed as Chief Scientific Officer at Indaptus Therapeutics, Inc..","evidence_excerpt":"Michael Newman, Ph.D. was appointed as Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"8778f0c844","claim":"Hoonmo Lee was appointed as Director at Indaptus Therapeutics, Inc..","evidence_excerpt":"each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a8eee38446","claim":"Michael Newman was appointed as Director at Indaptus Therapeutics, Inc..","evidence_excerpt":"each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}